Composition for delaying muscle attenuation based on yak skin peptide as well as preparation method and application of composition

Abstract

The invention relates to the technical field of compositions, and particularly discloses a composition for delaying muscle attenuation based on yak skin peptide as well as a preparation method and application thereof, and the composition is prepared from the following raw materials in parts by weight: 1.5-8.0 parts of yak skin peptide, 1.0-5.5 parts of lucid ganoderma, 1.0-8.0 parts of fructus lycii, 1.5-7.0 parts of rhizoma polygonati and 0.5-5.5 parts of radix notoginseng. The invention provides a composition for delaying muscle attenuation, which contains specific components of yak skin peptide, lucid ganoderma, fructus lycii, rhizoma polygonati and pseudo-ginseng, and breaks through the limitation of a conventional mode of improving a motor function by supplementing whey protein. The components are selected in specific parts by weight, and experimental research proves that the composition has a very remarkable improvement effect on delaying muscle attenuation and has a remarkable effect on improving the athletic ability.

Description

Technical Field

[0001] The present invention belongs to the technical field of compositions, and in particular relates to a composition for delaying muscle attenuation based on yak hide peptide, and a preparation method and application thereof. Background Art

[0002] Sarcopenia is an age-related degenerative syndrome characterized by a decrease in skeletal muscle mass, muscle strength, and / or physical activity. As the aging population intensifies, more and more elderly people are suffering from it. Sarcopenia increases the risk of falls and fractures, and patients' ability to live daily lives decreases. It may also be associated with heart disease, respiratory diseases, and cognitive impairment, leading to motor dysfunction, decreased quality of life, increased hospitalization costs, and care costs. Currently, delaying sarcopenia mainly involves supplementing high-quality protein (especially whey protein) and exercising. Whey protein is rich in branched-chain amino acids, especially leucine, and is considered an effective way to delay sarcopenia. It can increase muscle mass and promote muscle synthesis. However, long-term and excessive supplementation of whey protein may have a negative impact on the intestinal microbiota and also increase the burden on the kidneys.

[0003] Yak peptides may play an important role in human metabolism and exercise response. Skeletal muscle contraction triggers widespread changes in numerous cells, tissues, and organs. Yak peptides (which consist of fewer than 100 amino acids) and mitochondrial-derived peptides may act as exercise-sensitive peptides, playing a crucial role in exercise-induced physiological adaptations. This provides a theoretical basis for the development of a yak peptide-based composition to slow muscle attenuation. Therefore, developing a yak peptide-based composition with a clear composition, reasonable cost, and the ability to effectively slow muscle attenuation is of great practical significance. Summary of the Invention

[0004] The purpose of the present invention is to provide a composition for delaying muscle attenuation based on yak hide peptide, and its preparation method and application, so as to solve the problems raised in the above background technology.

[0005] To achieve the above object, the present invention provides the following technical solutions:

[0006] A composition for delaying muscle attenuation based on yak skin peptide, comprising the following raw materials in parts by weight: 1.5-8.0 parts of yak skin peptide, 1.0-5.5 parts of ganoderma lucidum, 1.0-8.0 parts of wolfberry, 1.5-7.0 parts of polygonatum, and 0.5-5.5 parts of panax notoginseng;

[0007] The yak skin peptide is a powdered product with oligopeptides having a relative molecular mass of less than 1000Da as the main component.

[0008] Preferably, the composition is composed of the following raw materials in parts by weight: 5.0 parts of yak skin peptide, 3.5 parts of Ganoderma lucidum, 3.5 parts of wolfberry, 3.5 parts of polygonatum, and 1.0 part of Panax notoginseng.

[0009] A method for preparing a composition for delaying muscle attenuation based on yak hide peptide, comprising the above-mentioned composition, wherein the preparation method comprises the following steps: separately preparing extracts of Ganoderma lucidum, wolfberry, Polygonatum sibiricum, and Panax notoginseng, and mixing yak hide peptide powder, Ganoderma lucidum extract, wolfberry extract, Polygonatum sibiricum extract, and Panax notoginseng extract in proportion to obtain a final product composition;

[0010] The preparation method of the Ganoderma lucidum extract is as follows: Ganoderma lucidum is extracted, concentrated, and dried to obtain the Ganoderma lucidum extract; the preparation method of the Lycium barbarum extract is as follows: Lycium barbarum is extracted, concentrated, precipitated with alcohol, and dried to obtain the Lycium barbarum extract; the preparation method of the Polygonatum sibiricum extract is as follows: Polygonatum sibiricum is extracted, concentrated, precipitated with alcohol, and dried to obtain the Polygonatum sibiricum extract; the preparation method of the Panax notoginseng extract is as follows: Panax notoginseng is extracted, concentrated, and dried to obtain the Panax notoginseng extract.

[0011] Preferably, the preparation method further comprises the following steps:

[0012] S1. Preparation of yak hide peptide freeze-dried powder: clean yak hide → chop → soak in 10 times the volume of distilled water for 24 hours → add complex protease (trypsin: neutral protease = 1:1, the ratio of total enzyme to raw material is 2000 U / g) → enzymatic hydrolysis at 50°C for 4 hours → boil to inactivate the enzyme for 10 minutes → centrifuge for 20 minutes (8000 rpm) → vacuum concentrate the supernatant → freeze-dry → grind through an 80-mesh sieve;

[0013] Take fresh yak hide, wash it thoroughly, cut the washed yak hide into small pieces, add distilled water equivalent to 10 times its weight to the chopped yak hide pieces, soak for 24 hours, add composite protease to the soaked mixture, wherein the composite protease comprises trypsin and neutral protease in a 1:1 ratio, and the total amount of enzyme added is controlled to be 2000U / g yak hide raw material, carry out enzymatic hydrolysis at 50°C for 4 hours, boil the enzymatic hydrolyzate for 10 minutes to completely inactivate the enzyme activity, and after the inactivated solution is cooled to room temperature, centrifuge at 8000rpm for 20 minutes. After centrifugation, collect the supernatant, vacuum concentrate the collected supernatant, place the concentrate in a freeze dryer for freeze drying, crush the freeze-dried solid, and pass it through an 80-mesh sieve to finally obtain a yak hide peptide freeze-dried powder product;

[0014] S2. Preparation of Ganoderma lucidum and Panax notoginseng extracts: Ganoderma lucidum and Panax notoginseng were extracted and concentrated to obtain extracts A and B respectively;

[0015] S3. Preparation of wolfberry fruit and polygonatum extracts: extract wolfberry fruit and polygonatum separately, concentrate, and precipitate with alcohol, and remove the lower precipitate to obtain wolfberry fruit and polygonatum extracts, which are recorded as extracts C and D, respectively;

[0016] S4. Preparation of a composition for delaying muscle attenuation based on yak hide peptide: the four extracts A, B, C and D are mixed evenly to prepare a dry powder; the dry powder is mixed evenly with yak hide peptide powder to obtain the composition.

[0017] Preferably, in the step S2, 8-12 times the total weight of water of Ganoderma lucidum and Panax notoginseng is added, and the mixture is extracted twice at 80-100°C, each time for 2 hours; in the step S3, 6-12 times the total weight of wolfberry and Polygonatum sibiricum is added, and the mixture is extracted twice at 80-100°C, each time for 2 hours, ethanol is added and the mixture is allowed to stand for stratification, and then the lower precipitate is removed, and the dry powders of the four extracts are evenly mixed with the yak hide peptide powder to obtain the composition.

[0018] The use of the above-mentioned composition in the preparation of medicine or food for delaying muscle attenuation.

[0019] A medicine comprising the above-mentioned composition, wherein the components of the medicine further include an excipient, wherein the excipient is at least one of a flavoring agent, a thickener, a disintegrant, and a filler;

[0020] The pharmaceutical dosage form is one of oral liquid, solid beverage, granules, capsules, and tablets.

[0021] In addition, the present invention provides the pharmaceutical dosage form, specifically one of oral liquid, solid beverage, granule, capsule, and tablet.

[0022] The present invention also provides a specific application of the composition for delaying muscle attenuation based on yak skin peptide in medicine. Specifically, the present invention provides a granule, comprising a composition for delaying muscle attenuation based on yak skin peptide, and the weight percentage of the composition for delaying muscle attenuation based on yak skin peptide in the granule is 60-90%. The present invention provides a solid beverage, comprising a composition for delaying muscle attenuation based on yak skin peptide, and the weight percentage of the composition for delaying muscle attenuation based on yak skin peptide in the solid beverage is 50-85%. The present invention provides an oral liquid, comprising a composition for delaying muscle attenuation based on yak skin peptide, and the weight percentage of the composition for delaying muscle attenuation based on yak skin peptide in the oral liquid is 10-30%.

[0023] Compared with the prior art, the present invention has the following beneficial effects:

[0024] The present invention provides a composition for delaying muscle attenuation, comprising specific ingredients: yak hide peptide, ganoderma lucidum, wolfberry fruit, polygonatum sibiricum, and Panax notoginseng. This composition overcomes the limitations of conventional whey protein supplementation for improving motor function. Experimental studies have demonstrated that these ingredients, when used in specific weight proportions, significantly improve muscle attenuation and enhance athletic performance. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 The present invention is a flow chart of a method for preparing a composition for delaying muscle attenuation based on yak hide peptide. DETAILED DESCRIPTION

[0026] The following will provide a clear and complete description of the technical solutions in the embodiments of the present invention in conjunction with the accompanying drawings. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. All other embodiments obtained by ordinary technicians in this field based on the embodiments of the present invention without making any creative efforts shall fall within the scope of protection of the present invention.

[0027] Example 1:

[0028] Formula: A composition for delaying muscle attenuation based on yak skin peptide in an embodiment of the present invention. The raw materials of the composition for delaying muscle attenuation in this embodiment are as follows: 5 parts of yak skin peptide, 3 parts of Ganoderma lucidum, 3 parts of wolfberry, 3 parts of Polygonatum sibiricum, and 1 part of Panax notoginseng.

[0029] Preparation method: The preparation method of a composition for delaying muscle attenuation based on yak hide peptide according to Example 1 of the present invention comprises the following steps:

[0030] (1) Yak skin peptide: Clean the yak skin thoroughly → cut into pieces → add 10 times the volume of distilled water and soak for 24 hours → add compound protease (trypsin: neutral protease = 1:1, the ratio of total enzyme amount to raw material is 2000U / g) → enzymatic hydrolysis at 50℃ for 4 hours → boil to inactivate the enzyme for 10 minutes → centrifuge for 20 minutes (8000rpmin) → vacuum concentrate the supernatant → freeze-dry → crush and pass through an 80-mesh sieve.

[0031] (2) Ganoderma lucidum and Panax notoginseng were extracted and concentrated to obtain extracts A and B; specifically, 10 times the total weight of water was added to Ganoderma lucidum and Panax notoginseng, respectively, and the mixture was extracted at 100°C for 2 hours, filtered, and 8 times the amount of water was added to the obtained residue, and the mixture was extracted at 100°C for 2 hours. The two filtrates were combined and concentrated to obtain extracts A and B.

[0032] (3) Extract, concentrate, and precipitate wolfberry and polygonatum, remove the lower precipitate, and record it as precipitate C and D respectively. Mix A, B, C, and D evenly and dry. Specifically, add 10 times the total weight of water to wolfberry and polygonatum, extract at 100℃ for 2h, filter, add 8 times the amount of water to the obtained medicinal residue, extract at 100℃ for 2h each time, combine the two filtrates and concentrate, concentrate to extract, add ethanol to the extract to make the alcohol precipitation concentration of 70%, remove the lower precipitate, add purified water to dissolve, mix with the previous Ganoderma lucidum and Panax notoginseng extract, add 2 parts of soluble starch to dry, and spray dry at an inlet temperature of 195℃ and an outlet temperature of 80℃. The dry powder is evenly mixed with yak skin peptide powder to obtain the composition for delaying muscle attenuation based on yak skin peptide.

[0033] Example 2:

[0034] The only difference between this embodiment and embodiment 1 is that the raw materials of the composition for delaying muscle attenuation based on yak skin peptide are as follows: 10 parts of yak skin peptide, 6 parts of Ganoderma lucidum, 6 parts of wolfberry, 6 parts of Polygonatum sibiricum, and 2 parts of Panax notoginseng.

[0035] Example 3:

[0036] The only difference between this embodiment and embodiment 1 is that the composition for delaying muscle attenuation comprises the following raw materials: 5 parts of yak skin peptide, 3.5 parts of Ganoderma lucidum, 3.5 parts of wolfberry, 3.5 parts of Polygonatum sibiricum, and 1 part of Panax notoginseng.

[0037] Animal experiments:

[0038] Animals: 180 SPF male Sprague-Dawley rats, 6 weeks old. The distribution of rats into the groups is shown in Table 1. Rats were housed in an SPF animal room maintained in a quiet, clean, well-ventilated, and appropriately illuminated environment. The room's temperature was 23 ± 2°C, the humidity was 40%–70%, and the light–dark cycle was 12 h. The rats were provided with free access to sterile water and feed, and the bedding was changed every 3 days (autoclaved). Five rats were housed per cage during the entire period.

[0039] Experimental methods:

[0040] (1) Modeling: After 3 days of adaptive feeding, 30 rats were randomly selected according to body weight as the blank control group (CON group) and injected with normal saline (0.5 mg / kg) daily. The remaining animals were given dexamethasone (Dex) injection (1.0 mg / kg) via intraperitoneal injection to establish the sarcopenia syndrome model. Body weight was measured twice a week, and the grip strength of the rats was measured 7 and 14 days after modeling. After 14 days, the gastrocnemius, soleus, tibialis anterior, and plantaris muscles of 6 rats in the CON group and 6 rats in the Dex group were harvested to measure the muscle modulus and muscle fiber diameter.

[0041] (2) Test substance intervention: After modeling, the model group rats were randomly divided into five groups according to their body weight, namely, the self-recovery group, the Dex group, the Dex + Example 1 (2.0 g / kg), the Dex + Example 2 (2.0 g / kg), and the Dex + Example 3 (2.0 g / kg), with 30 rats in each group. The specific experimental methods are shown in Table 1.

[0042] Table 1. Test substance intervention experimental methods

[0043]

[0044] Body weight was measured twice weekly. Grip strength was measured on days 7, 14, 21, 28, and 35 after the start of the intervention. Muscle mass index and fiber diameter were measured in the gastrocnemius, soleus, tibialis anterior, and plantaris muscles on days 14, 21, 28, and 35 to determine whether the yak hide peptide-based composition of the present invention improves muscle attenuation.

[0045] (3) Observation indicators: Body weight, twice a week, observe the weight gain trend and eating habits of rats; rat grip strength test, use a digital handgrip dynamometer to measure the grip strength of rats on the 7th and 14th day after modeling, and on the 14th, 21st, 28th and 35th day after intervention. The specific operation is as follows: After the rats adapt to the environment for 10 minutes, the grip strength test begins. The rats grasp the metal pull rod of the digital handgrip dynamometer, grasp the rat's tail, and gradually pull backward with force until the rat releases the metal pull rod. The force at the time of release is recorded as the maximum tension. Each rat is tested 5 times, with an interval of 40 minutes between each test; rat endurance test, the rats run on a 6-channel treadmill until exhaustion, and the treadmill is set to a certain slope. The criterion for judging exhaustion is that the rat is not afraid of the electrical stimulation at the end of the channel and crawls motionlessly. Monitoring indicators included running distance and time; muscle wet weight and coefficient: gastrocnemius, soleus, tibialis anterior, and plantaris muscles were weighed and recorded 14 days after modeling and 14, 21, 28, and 35 days after intervention, and the ratio of each muscle to total body weight was calculated. Muscle coefficient = muscle wet weight / body weight; muscle fiber diameter: HE staining was performed on muscles 14 days after modeling and 14, 21, 28, and 35 days after intervention, and 300-500 muscle fibers in each sample were used to calculate the muscle fiber diameter of gastrocnemius, soleus, tibialis anterior, and plantaris muscles, and the average value was taken.

[0046] (4) Statistical methods and result determination: SpSS 30.0 software was used for data statistical analysis. Body weight, grip strength, muscle mass (gastrocnemius and soleus), muscle coefficient, and muscle fiber diameter were all measured data and expressed as mean ± standard deviation. If the data met the normal distribution and homogeneity of variance, a completely randomized design variance analysis was used for statistical analysis. If p < 0.05, Dunnett-t was used to further compare each dose group of the test substance with the model control group. If the data did not meet the normal distribution and homogeneity of variance, appropriate variable transformation was performed. After meeting the normality or homogeneity of variance requirements, the transformed data was used for statistics. If the variable transformation still did not meet the normality or homogeneity of variance requirements, the rank sum test was used for statistics.

[0047] Result determination: During the modeling stage, compared with the blank control group, any one of the indicators of grip strength, muscle coefficient, and muscle fiber diameter of the four muscles of the rats in the model control group was reduced and statistically significant, and the muscle attenuation syndrome model was considered to be successfully established; during the intervention stage, compared with the Dex group, any one of the indicators of grip strength, muscle coefficient, and muscle fiber diameter of the four muscles of the Dex+ example group was increased and statistically significant, and it can be determined that the yak skin peptide-based composition of the present invention has the effect of improving dexamethasone-induced muscle atrophy in rats.

[0048] Experimental results:

[0049] (1) Effect of Dex on the weight gain trend of rats: As shown in Table 2, intraperitoneal injection of Dex led to a decrease in rat weight. From the third day of modeling to the end of modeling, the body weight of rats in the model control group decreased significantly compared with the blank control group (p < 0.01).

[0050] Table 2. Effects of Dex on rat body weight (g)

[0051]

[0052] Note: Compared with the blank control group, *: p < 0.05, **: p < 0.01.

[0053] (2) Effect of Dex on the gripping strength of rats: As shown in Table 3, at the beginning of modeling, there was no difference in gripping strength between the blank control group and the model control group. However, after modeling, the gripping strength of rats in the model control group was significantly reduced compared with that in the blank control group (p<0.01).

[0054] Table 3. Effects of Dex on the grip strength of rats

[0055]

[0056] Note: Compared with the blank control group, **: p < 0.01.

[0057] (3) Effect of Dex on the muscle coefficient of rats: As shown in Table 4, after the modeling, the muscle fibers of the gastrocnemius, soleus, tibialis anterior and plantaris muscles of the rats in the model control group were reduced compared with those in the blank control group, and the difference was statistically significant (p<0.05).

[0058] Table 4. Effects of Dex on muscle mass index in rats

[0059]

[0060] Note: Compared with the blank control group, *: p < 0.05, **: p < 0.01.

[0061] (4) Effect of yak skin peptide combination on weight gain trend of rats: After 5 weeks of intervention with yak skin peptide combination, the weight of rats in each group showed an increasing trend. However, there was no significant difference in the weight of rats in the yak skin peptide combination group compared with the Dex group (p>0.05).

[0062] Compared with the Dex group, the grip strength of the yak skin peptide composition 1, 2, and 3 intervention groups increased at week 4 and week 5 (p<0.05), among which the grip strength of the composition 3 group increased more significantly (p<0.01). The results are shown in Table 5.

[0063] Table 5. Effect of yak skin peptide composition on the grip strength of rats

[0064]

[0065] Note: Compared with the Dex group, *: p < 0.05, **: p < 0.01.

[0066] (5) Effect of yak skin peptide composition on rat endurance: The effect of yak skin peptide composition on rat endurance was determined by the distance and time the rats ran on a treadmill. The experimental results showed that after intervention with yak skin peptide compositions 1, 2, and 3, the rat endurance was significantly improved compared with the Dex group (p < 0.05), with composition 3 having a greater effect than composition 1 and composition 2. The results are shown in Table 7.

[0067] Table 7. Effects of yak skin peptide composition on rat endurance

[0068]

[0069] Note: Compared with the Dex group, *: p < 0.05, **: p < 0.01.

[0070] (6) Effect of yak skin peptide composition on muscle coefficient of rats: As shown in Table 8, compared with the Dex group, yak skin peptide compositions 1, 2, and 3 effectively increased the muscle coefficients of the gastrocnemius and plantaris muscles of rats after 3 weeks of intervention (p < 0.05), among which the effect of yak skin peptide composition 3 was better than that of compositions 1 and 2.

[0071] Table 8. Effect of yak skin peptide composition on muscle coefficient of rats

[0072]

[0073]

[0074] Note: Compared with the Dex group, *: p < 0.05, **: p < 0.01.

[0075] Experimental Conclusion

[0076] In summary, compared with the blank control group, the weight of rats in the Dex group decreased significantly with the extension of modeling time. At the end of modeling, the weight and grip strength of rats in the Dex group decreased significantly, and the muscle coefficients of the gastrocnemius, soleus, tibialis anterior, and plantaris muscles decreased, indicating that the model was successful.

[0077] The yak hide peptide combination was administered for a total of 35 days, with samples collected at 14, 21, 28, and 35 days to observe changes in various indicators. Two behavioral indicators (grip strength test and treadmill test) showed that compared with the Dex group, the yak hide peptide combination group 3 significantly improved grip strength and endurance, surpassing combination 1 and combination 2.

[0078] As can be seen from the above, the present invention provides a composition for delaying muscle attenuation, comprising specific ingredients: yak hide peptide, Ganoderma lucidum, wolfberry fruit, Polygonatum sibiricum, and Panax notoginseng. This composition overcomes the limitations of conventional whey protein supplementation for improving motor function. Experimental studies have demonstrated that these ingredients, when used in specific weight proportions, significantly improve muscle attenuation and enhance athletic performance.

[0079] In the description of this specification, the reference terms "one embodiment", "some embodiments", "examples", "specific examples" or "some examples" mean that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic expressions of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art can combine and combine different embodiments or examples described in this specification and features of different embodiments or examples without contradiction.

[0080] In the drawings of the embodiments disclosed in the present invention, only the structures related to the embodiments disclosed in the present invention are involved. Other structures can refer to the general design. In the absence of conflict, the same embodiment and different embodiments of the present invention can be combined with each other.

[0081] While embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions, and variations may be made to these embodiments without departing from the principles and spirit of the invention, and that the scope of the invention is defined by the appended claims and their equivalents.

Claims

1. A composition for delaying muscle attenuation based on yak skin peptide, characterized in that: The invention comprises the following raw materials in parts by weight: 1.5-8.0 parts of yak skin peptide, 1.0-5.5 parts of ganoderma lucidum, 1.0-8.0 parts of wolfberry, 1.5-7.0 parts of polygonatum, and 0.5-5.5 parts of panax notoginseng; The yak skin peptide is a powdered product with oligopeptides having a relative molecular mass of less than 1000Da as the main component.

2. The composition for delaying muscle attenuation based on yak skin peptide according to claim 1, characterized in that: The composition is composed of the following raw materials in parts by weight: 5.0 parts of yak skin peptide, 3.5 parts of ganoderma lucidum, 3.5 parts of wolfberry, 3.5 parts of polygonatum, and 1.0 part of panax notoginseng.

3. A method for preparing a composition for delaying muscle attenuation based on yak skin peptide, characterized in that: The composition according to any one of claims 1 to 2, wherein the preparation method of the composition comprises the following steps: preparing extracts of Ganoderma lucidum, wolfberry, Polygonatum sibiricum, and Panax notoginseng respectively, and mixing yak hide peptide powder, Ganoderma lucidum extract, wolfberry extract, Polygonatum sibiricum extract, and Panax notoginseng extract according to a certain proportion to obtain a final product composition; The preparation method of the Ganoderma lucidum extract is as follows: Ganoderma lucidum is extracted, concentrated, and dried to obtain the Ganoderma lucidum extract; the preparation method of the Lycium barbarum extract is as follows: Lycium barbarum is extracted, concentrated, precipitated with alcohol, and dried to obtain the Lycium barbarum extract; the preparation method of the Polygonatum sibiricum extract is as follows: Polygonatum sibiricum is extracted, concentrated, precipitated with alcohol, and dried to obtain the Polygonatum sibiricum extract; the preparation method of the Panax notoginseng extract is as follows: Panax notoginseng is extracted, concentrated, and dried to obtain the Panax notoginseng extract.

4. The method for preparing a composition for delaying muscle attenuation based on yak skin peptide according to claim 3, characterized in that: The following steps are also included: S1. Preparation of yak skin peptide freeze-dried powder: fresh yak skin is taken and thoroughly cleaned. The cleaned yak skin is cut into small pieces. Distilled water with a volume equivalent to 10 times its weight is added to the chopped yak skin pieces and soaked for 24 hours. Composite protease is added to the soaked mixture, wherein the composite protease comprises trypsin and neutral protease in a 1:1 ratio, and the total amount of enzyme added is controlled to be 2000U / g yak skin raw material. Enzyme hydrolysis reaction is carried out at 50°C for 4 hours. The enzymatic hydrolysis solution is boiled for 10 minutes to completely inactivate the enzyme activity. After the inactivated solution is cooled to room temperature, it is centrifuged at 8000rpm for 20 minutes. After centrifugation, the supernatant is collected and vacuum concentrated. The concentrated solution is placed in a freeze dryer for freeze drying. The freeze-dried solid is crushed and passed through an 80-mesh sieve to finally obtain the finished yak skin peptide freeze-dried powder; S2. Preparation of Ganoderma lucidum and Panax notoginseng extracts: Ganoderma lucidum and Panax notoginseng were extracted and concentrated to obtain extracts A and B respectively; S3. Preparation of wolfberry fruit and polygonatum extracts: extract wolfberry fruit and polygonatum separately, concentrate, and precipitate with alcohol, and remove the lower precipitate to obtain wolfberry fruit and polygonatum extracts, which are recorded as extracts C and D, respectively; S4. Preparation of a composition for delaying muscle attenuation based on yak hide peptide: the four extracts A, B, C and D are mixed evenly to prepare a dry powder; the dry powder is mixed evenly with yak hide peptide powder to obtain the composition.

5. The method for preparing a composition for delaying muscle attenuation based on yak skin peptide according to claim 4, characterized in that: In the step S2, 8-12 times the total weight of Ganoderma lucidum and Panax notoginseng are added with water, and the mixture is extracted twice at 80-100° C. for 2 hours each time; in the step S3, 6-12 times the total weight of Lycium barbarum and Polygonatum sibiricum are added with water, and the mixture is extracted twice at 80-100° C. for 2 hours each time, ethanol is added, and the mixture is allowed to stand for stratification, and then the lower precipitate is removed, and the dry powders of the four extracts are evenly mixed with the yak hide peptide powder to obtain the composition.

6. Use of the composition according to claims 1-2 in the preparation of a drug or food for delaying muscle attenuation.

7. A drug, characterized in that The drug comprises the composition according to any one of claims 1 to 2, and the components of the drug further include excipients, wherein the excipients are at least one of a flavoring agent, a thickener, a disintegrant, and a filler; The pharmaceutical dosage form is one of oral liquid, solid beverage, granules, capsules, and tablets.

8. A granule, characterized in that: The invention comprises the composition according to any one of claims 1 to 2, wherein the weight percentage of the composition in the granules is 60-90%.

9. A solid beverage, characterized in that The composition according to any one of claims 1 to 2 is present in a solid beverage in an amount of 50-85% by weight.

10. An oral liquid, characterized in that: The composition according to any one of claims 1 to 2, wherein the weight percentage of the composition in the oral liquid is 10-30%.

Images